Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR

  • Felici A
  • Bria E
  • Tortora G
 et al. 
  • 6

    Readers

    Mendeley users who have this article in their library.
  • 12

    Citations

    Citations of this article.

Abstract

With seven targeted agents, directed against the VEGF/VEGF receptor (VEGFR) axis or the mTOR pathway, approved for the treatment of metastatic renal cell carcinoma and more active agents in advanced phase of clinical testing, questions have arisen with regard to their optimal use, either in combination or in sequence. One of the most compelling (and debated) issues is whether continued VEGF/VEGFR inhibition with agents hitting the same targets (TKI-TKI) affords better results than switching mechanisms of action by alternating VEGFR and mTOR inhibition (TKI-mTOR). In this article, the authors review the (little) available evidence coming from randomized Phase III clinical trials and try to fill in the (many) remaining gaps using evidence from small-size, single-arm Phase II studies and retrospective series, as well as reviewing preclinical evidence supporting either strategy.

Author-supplied keywords

  • VEGF receptor-tyrosine kinase inhibitor
  • mTOR inhibitors
  • metastatic
  • renal cell carcinoma
  • second-line treatment
  • sequential therapy

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

  • Alessandra Felici

  • Emilio Bria

  • Giampaolo Tortora

  • Francesco Cognetti

  • Michele Milella

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free